Surgical Oncology
Volume 19, Issue 1 , Pages 27-32 , March 2010

Breast cancer chemoresistance: Emerging importance of cancer stem cells

  • Suebwong Chuthapisith

      Affiliations

    • Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
    • Corresponding Author InformationCorresponding author. Tel.: +66 2 419 8016; fax: +66 2 412 9160.
    • ,
  • Jennifer Eremin

      Affiliations

    • Department of Research and Development, Lincoln County Hospital, Lincoln, UK
    • ,
  • Mohamed El-Sheemey

      Affiliations

    • Department of Research and Development, Lincoln County Hospital, Lincoln, UK
    • Department of Forensic and Biomedical Sciences, Faculty of Health, Life and Social Sciences, University of Lincoln, UK
    • ,
  • Oleg Eremin

      Affiliations

    • Department of Research and Development, Lincoln County Hospital, Lincoln, UK
    • Department of Surgery, Queen's Medical Centre, Nottingham, UK

,Accepted 26 January 2009.

References 

  1. Jordan CT. Cancer stem cell biology: from leukemia to solid tumors. Curr Opin Cell Biol. 2004;16:708–712
  2. Askenasy N, Yaniv I, Stein J, Sharkis SJ. Our perception of developmental plasticity: esse est percipi (to be is to be perceived)?. Curr Stem Cell Res Ther. 2006;1:85–94
  3. Kiger AA, White-Cooper H, Fuller MT. Somatic support cells restrict germline stem cell self-renewal and promote differentiation. Nature. 2000;407:750–754
  4. Bellantuono I, Keith WN. Stem cell ageing: does it happen and can we intervene?. Expert Rev Mol Med. 2007;9:1–20
  5. Gordon MY, Levicar N, Pai M, Bachellier P, Dimarakis I, Al Allaf F, et al. Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells. 2006;24:1822–1830
  6. Levicar N, Pai M, Habib NA, Tait P, Jiao LR, Marley SB, et al. Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease. Cell Prolif. 2008;41(Suppl 1):115–125
  7. Balsam LB, Robbins RC. Haematopoietic stem cells and repair of the ischaemic heart. Clin Sci (Lond). 2005;109:483–492
  8. Dimarakis I, Habib NA, Gordon MY. Adult bone marrow-derived stem cells and the injured heart: just the beginning?. Eur J Cardiothorac Surg. 2005;28:665–676
  9. Levicar N, Dimarakis I, Flores C, Tracey J, Gordon MY, Habib NA. Stem cells as a treatment for chronic liver disease and diabetes. Handb Exp Pharmacol. 2007;180:243–262
  10. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115:1503–1521
  11. Spillane JB, Henderson MA. Cancer stem cells: a review. ANZ J Surg. 2007;77:464–468
  12. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284
  13. Hamburger A, Salmon SE. Primary bioassay of human myeloma stem cells. J Clin Invest. 1977;60:846–854
  14. Southam CM, Brunschwig A. Quantitative studies of autotransplantation of human cancer. Cancer. 1960;14:971–978
  15. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730–737
  16. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111
  17. Gudjonsson T, Magnusson MK. Stem cell biology and the cellular pathways of carcinogenesis. APMIS. 2005;113:922–929
  18. Li P, Barraclough R, Fernig DG, Smith JA, Rudland PS. Stem cells in breast epithelia. Int J Exp Pathol. 1998;79:193–206
  19. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133(+) and CD133(−) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67:4010–4015
  20. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–115
  21. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104:10158–10163
  22. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988
  23. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65:5506–5511
  24. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. Mol Pathol. 1999;52:189–196
  25. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615–5621
  26. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11:259–273
  27. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101:14228–14233
  28. Challen GA, Little MH. A side order of stem cells: the SP phenotype. Stem Cells. 2006;24:3–12
  29. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797–1806
  30. Chuthapisith S, Robins RA, Eremin O. Increased presence of stem/progenitor cell subtypes. In: Proceedings of the 99th annual meeting of the American Association for Cancer Research; Apr 12–16 2008; San Diego, CA, Philadelphia (PA): AACR; Abstract number 3205; 2008.
  31. Steiniger SCJ, Coppinger JA, Kruger JA, Yates J, Janda KD. Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells. 2008;26:3037–3046
  32. Phillips TM, McBride WH, Pajonk F. The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98:1777–1785
  33. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760
  34. Jelski W, Zalewski B, Szmitkowski M. Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with liver cancer. J Clin Lab Anal. 2008;22:204–209
  35. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell. 2007;1:555–567
  36. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE. 2008;3:e2428
  37. Bao F, Polk P, Nordberg ML, Veillon DM, Sun A, Deininger M, et al. Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007;31:1511–1520
  38. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8:R59
  39. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005;11:1154–1159
  40. Hellman S, Botnick L, Mauch P. Stem-cell biology and cancer therapy: the more things change. J Clin Oncol. 2008;26:821–822
  41. Massard C, Deutsch E, Soria JC. Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol. 2006;17:1620–1624
  42. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895–902
  43. Yang CH, Huang CJ, Yang CS, Chu YC, Cheng AL, Whang-Peng J, et al. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res. 2005;65:6943–6949
  44. Takigawa N, Takeyama M, Kozuki T, Shibayama T, Hisamoto A, Kiura K, et al. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells. Oncol Rep. 2007;17:983–987
  45. Baguley BC. Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent Pat Anticancer Drug Discov. 2006;1:121–127
  46. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol. 2004;22:4217–4226

PII: S0960-7404(09)00005-X

doi: 10.1016/j.suronc.2009.01.004

Surgical Oncology
Volume 19, Issue 1 , Pages 27-32 , March 2010

Article Tools

* Image Usage & Resolution